Rosetta Genomics to Receive U.S. Patent for Cancer Origin Assay

Rosetta Genomics to Receive U.S. Patent for Cancer Origin Assay 
Covers Method of Identifying Tumor of Origin in Cancer of Unknown
Primary or Metastatic Cancer; Expands Company's Leading IP Position
in the Growing Area of microRNA Biomarkers 
PRINCETON, NJ and REHOVOT, ISRAEL -- (Marketwired) -- 04/04/14 -- 
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics and therapeutics,
today announced that the Company received a Notice of Allowance from
the United States Patent and Trademark Office (USPTO) for a patent
covering the method of use of a core element of Rosetta Genomics'
microRNA technology in the identification of the tumor of origin in
cancer of unknown or uncertain primary and metastatic cancer. The
issued claims for U.S. Patent Application No. 13/167,489 is entitled
"Gene Expression Signature for Classification of Tissue of Origin of
Tumor Samples."  
The invention covered by this patent relates to the methods for
determining an expression profile with a primer sequence and the
comparison of the expression profile that quantitates 48 microRNAs
and assigns one of 25 tumor diagnoses using a biologically motivated
binary decision tree and a K-Nearest Neighbors classifier to identify
the tumor of origin. This patent protects the intellectual property
of the Company's first generation Cancer Origin Test, which utilizes
a polymerase chain reaction (PCR) technology for sequencing.  
"We are pleased to expand our intellectual property portfolio with
this new U.S. patent. While this patent covers our first generation
assay, it is still critical to our patent strategy as it creates a
barrier to entry for would-be competitors and solidifies our position
as the leader in microRNA biomarker technology and microRNA-based
diagnostics," noted Kenneth A. Berlin, President and Chief Executive
Officer of Rosetta Genomics. "This patent is important as it protects
key elements of our microRNA technology and could be indicative of
the future receipt of patent protection for our other existing and
future assays. We continue to build a strong intellectual property
position to protect our expanding portfolio of microRNA-based
diagnostics and therapeutics."  
About Rosetta Cancer Testing Services 
 Rosetta Ca
ncer Tests are a
series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test(TM) can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). Rosetta
Mesothelioma Test(TM) diagnoses mesothelioma, a cancer connected to
asbestos exposure. The Rosetta Lung Cancer Test(TM) accurately
identifies the four main subtypes of lung cancer using small amounts
of tumor cells. The Rosetta Kidney Cancer Test(TM) accurately
classifies the four most common kidney tumors: clear cell renal cell
carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.
Rosetta's assays are designed to provide objective diagnostic data;
it is the treating physician's responsibility to diagnose and
administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the
Rosetta Cancer Origin Test(TM), 60,000 from the Rosetta Mesothelioma
Test(TM), 65,000 from the Rosetta Kidney Cancer Test(TM) and 226,000
patients from the Rosetta Lung Cancer Test(TM). The Company's assays
are offered directly by Rosetta Genomics in the U.S., and through
distributors around the world. For more information, please visit Parties interested in ordering the test can
contact Rosetta Genomics at (215) 382-9000 ext. 309. 
About Rosetta Genomics
 Founded in 2000, Rosetta's integrative
research platform combining bioinformatics and state-of- the-art
laboratory processes has led to the discovery of hundreds of
biologically validated novel human microRNAs. Building on its strong
patent position and proprietary platform technologies, Rosetta is
working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic
tools and therapeutics. Rosetta currently commercializes a full range
of microRNA-based molecular diagnostics. Rosetta's cancer testing
services are commercially available through its Philadelphia-based
CAP-accredited, CLIA-certified lab. For more information, please
Forward-Looking Statement Disclaimer
 Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta's Cancer of Origin
Test(TM), Rosetta's development or commercialization of molecular
 the market acceptance of Rosetta's cancer testing
services, particularly the Rosetta Cancer Origin Test(TM), Rosetta's
development of personalized medicine products and services, Rosetta
achieving further patent protection for its existing and future
assays and Rosetta building a strong intellectual property position,
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act
of 1995. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including those risks more fully discussed in the "Risk
Factors" section of Rosetta's Annual Report on Form 20-F for the year
ended December 31, 2012 as filed with the SEC. In addition, any
forward-looking statements represent Rosetta's views only as of the
date of this release and should not be relied upon as representing
its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required
by law. 
Company Contact: 
Rosetta Genomics 
Ken Berlin
President & CEO 
(609) 419-9003 
Investor Contacts: 
Anne Marie Fields
(212) 838-3777 
Bruce Voss
(310) 691-7100 
Press spacebar to pause and continue. Press esc to stop.